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Abstract: Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis affecting 5 million adults in the 
United States, with an age-adjusted prevalence of 4% to 15% and increasing up to 30% with age and the presence of car-
diovascular risk factors. In this article we focus on lower extremity PAD and specifically on the superficial femoral and 
proximal popliteal artery (SFPA), which are the most common anatomic locations of lower extremity atherosclerosis. We 
summarize current evidence and perform a systematic review on the diagnostic evaluation as well as the medical, endo-
vascular and surgical management of SFPA disease.  
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INTRODUCTION 
  Peripheral arterial disease (PAD) is a common manifesta-
tion of atherosclerosis and is defined as any pathologic pro-
cess causing obstruction to blood flow in the arteries, exclu-
sive of the coronary and cerebral vascular beds [1]. PAD 
affects a large segment of the adult population, with an age-
adjusted prevalence of 4% to 15%, affecting more than 5 
million adults in the United States [2, 3] and increasing up to 
30% with age (Fig. (1)) and the presence of cardiovascular 
risk factors [4]. Less than 20% of patients with PAD have 
typical symptoms of intermittent claudication –i.e., leg-   
 
 
*Address for correspondence to this author at the Division of Cardiovascu-
lar Medicine, University of Michigan, 2A394, 1500 E. Medical Center 
Drive, Ann Arbor, MI 48109-5853, USA; Tel: 734- 232-4276; Fax: 734-
764-4142; E-mail: hgurm@med.umich.edu 
muscle discomfort on exertion that is relieved by rest–, or 
critical limb ischemia – i.e., “rest pain”, ulceration or gan-
grene– [4, 5], whereas another third have atypical exertional 
leg symptoms [6]. 
  Age and gender-adjusted risk factors associated with the 
development of PAD are similar to the traditional risk fac-
tors for atherosclerosis, including cigarette smoking, diabe-
tes, hyperlipidemia, hypertension, hyperhomocystinemia and 
chronic renal insufficiency (Fig. (2)) [1, 2, 7]. Smoking and 
diabetes mellitus are the strongest risk factors and are asso-
ciated with more aggressive disease progression. The relative 
risk of intermittent claudication is 3.7 in current smokers and 
3.0 in ex-smokers [8], whereas the presence of diabetes in-
creases the risk of PAD by 2- to 4-fold with 5- to 10-times 
higher need for major amputation in diabetics compared to 
non-diabetics [2, 9]. 
 
Fig. (1). Weighted mean prevalence of intermittent claudication (symptomatic PAD) in large population-based studies. Reproduced with 
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Fig. (2). Approximate range of odds ratios for risk factors for symp-
tomatic peripheral arterial disease. Reproduced with permission 
from [7]. 
  Studies of the natural history of PAD indicate that the 
risk of ischemic limb events for non-diabetic patients is rela-
tively low, with less than 2% requiring major or minor am-
putation [1, 7, 10]. However, cardiovascular disease and 
manifestations of atherosclerosis in other vascular beds are 
the major determinants of prognosis in these patients. There 
is approximately a 2- to 4-fold increase in coronary and 
cerebrovascular disease in patients with PAD, with an annual 
rate of 5-7% of cardiovascular events, i.e. myocardial infarc-
tion, stroke, or death from cardiovascular causes [1, 5, 7, 11]. 
Notably, the risk of cardiovascular morbidity and mortality 
is equally high in patients with PAD, regardless of the pres-
ence of symptoms [5, 12]. Therefore, management of the 
disease should be directed not only at improving symptoms 
of claudication and lower limb ischemia, but more impor-
tantly at reducing the overall cardiovascular risk.  
  In this article we focus on lower extremity PAD and spe-
cifically on the superficial femoral and proximal popliteal 
artery (SFPA), which are the most common anatomic loca-
tions of lower extremity atherosclerosis. We summarize cur-
rent evidence on the diagnostic evaluation as well as the 
medical, endovascular and surgical management of SFPA 
disease.  
DIAGNOSTIC EVALUATION 
  The initial evaluation should include a careful history and 
physical examination with shoes and socks removed to as-
sess for signs of acute or chronic peripheral ischemia, with 
attention to peripheral pulses, hair loss, skin color and tro-
phic skin changes. The abdomen should be examined for 
evidence of an aortic aneurysm and blood pressure should be 
 
Fig. (3). Algorithm for diagnosis of peripheral arterial disease. TBI – toe brachial index; VWF – velocity wave form; PVR – pulse volume 
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measured in both arms. Auscultation for bruits at the neck 
and over the clavicles, abdomen and femoral pulses should 
also be performed. Upon clinical suspicion for PAD, referral 
to the vascular laboratory is the initial step for noninvasive 
diagnostic assessment of the location and severity of the ar-
terial disease (Fig. (3)). These noninvasive tests can also be 
repeated over time to follow disease progression and re-
sponse to medical treatment or revascularization.  
Ankle-Brachial, Toe-Brachial Indices and Segmental 
Pressure Measurements 
  The ankle-brachial index (ABI) is the single best initial 
screening test to perform in a patient with suspected PAD. 
The ABI is the ratio of the highest systolic ankle pressure to 
the highest arm pressure (in mmHg), obtained with a hand-
held Doppler instrument and a blood pressure cuff [1, 7]. A 
ratio of <0.90 is considered abnormal, with mild obstruction 
defined as a ratio of 0.71-0.90, moderate as 0.41-0.70 and 
severe when the ABI ratio is less than 0.40. Both arm pres-
sures must be recorded, since even in normal individuals, 
there is a minimal (less than 12 mmHg) inter-arm systolic 
pressure gradient which may be amplified in patients with 
atherosclerotic subclavian or axillary arterial disease. Subse-
quently, the higher arm blood pressure is used for the ABI 
ratio calculation. In addition, pulse wave reflection causes 
the ankle pressures to be 10-15 mmHg higher than the bra-
chial systolic pressure, which gives a normal ABI of greater 
than 1.00. The overall accuracy of the ABI to establish the 
diagnosis of lower extremity PAD has been validated with a 
sensitivity of 79-95% and a specificity of 96-100%, based on 
different studies [13, 14]. Overall, it is considered to have 
low inter-observer variability with a reproducibility of ap-
proximately 0.10. Apart from establishing the PAD diagno-
sis, the ABI also has prognostic value in identifying patients 
at risk for subsequent critical leg ischemia as well as cardio-
vascular morbidity and mortality and can also be used to 
assess disease progression after vascular surgery [1]. Fur-
thermore, it is a quick and cost-effective way to screen tar-
geted patients at risk for lower extremity PAD, including 
individuals 50 years or younger with history of diabetes and 
one other risk factor; those 50 to 69 years with history of 
smoking or diabetes; those 70 years and older; and those 
with abnormal pulse examination or known atherosclerotic 
disease in other vascular beds [1, 4, 7, 9]. 
  ABI measurement in the vascular lab is used in conjunc-
tion with segmental pressure measurements with plethys-
mographic cuffs placed sequentially along the limb at vari-
ous locations to accurately determine the location of individ-
ual artery stenosis. A systolic pressure gradient greater than 
20 mmHg between adjacent segments is considered in most 
laboratories to be indicative of a physiologically important 
focal stenosis. 
  The major limitation of the ABI and the segmental pres-
sure analysis is that they may be inaccurate in individuals 
with noncompressible arteries due to medial calcification, 
such as patients with long-standing diabetes, elderly patients 
and those with end-stage renal disease on dialysis. Such non-
compressible arteries should be suspected when the ABI is 
greater than 1.3 or when the lower extremity systolic pres-
sure is more than 20% higher than the brachial systolic pres-
sure. In such cases, accurate diagnostic information can be 
obtained by calculating the toe-brachial index and values less 
than 0.7 are considered diagnostic for lower extremity PAD 
[1, 7, 15]. The test is performed by placement of a small cuff 
on the proximal portion of the great or second toe and meas-
urement of the systolic perfusion pressure with the use of a 
plethysmographic device. 
Pulse-Volume Recordings and Continuous-Wave Dop-
pler Ultrasound 
  Pulse volume recordings (PVR) are based on the concept 
that arterial inflow into the lower extremities is pulsatile 
leading to measurable changes in the lower-limb volume 
with each cardiac cycle. These volumetric changes can be 
documented and graphed sequentially along the limb with 
the use of a plethysmographic technique. The magnitude of 
the pulse upstroke and pulse volume (amplitude) correlates 
with the blood flow and a sequential decrease signifies the 
presence of a flow-limiting lesion in the more proximal arte-
rial segment.  
  Continuous-wave Doppler ultrasound is used in conjunc-
tion with the PVR to obtain segmental velocity waveforms 
and systolic blood pressure measurements along the upper or 
lower extremities. A commonly used term is the peak-to-
peak pulsatility index, defined as the peak systolic velocity 
minus the minimum or most reversed diastolic velocity, di-
vided by the mean blood flow velocity. A decrease in the 
pulsatility index between the adjacent proximal and the distal 
arterial segments indicates the presence of physiologic sig-
nificant stenosis. One important limitation is the pulse nor-
malization distal to some arterial stenoses, within a short 
distance from the lesion [16]. The analysis of the morphol-
ogy of the Doppler waveform can also provide useful local-
izing information, i.e. the combination of low-resistance 
Doppler waveform and low pulsatility index within an arte-
rial segment would indicate an occlusion proximal to that 
segment. One notable exception is the presence of superficial 
femoral artery disease, where, in the absence of aortoiliac 
disease, there is a low resistance waveform and low pulsatil-
ity index in the common femoral artery resulting in a false 
positive study suggesting aortoiliac disease [17].  
  Both PVR and Doppler waveform techniques can provide 
accurate information even in patients with noncompressible 
vessels and are used to establish the initial diagnosis, assess 
the location and severity of lower extremity PAD as well as 
to follow the progression after a revascularization procedure 
[1, 7].  
Treadmill Exercise Testing with and without ABI 
  Exercise testing can be useful in establishing the diagno-
sis of PAD when there is a high index of suspicion and the 
resting ABI measurements are normal, i.e. in patients with 
isolated iliac stenosis. A decrease in ABI of 15%-20% with 
exercise would be diagnostic of PAD [1, 7]. Most laborato-
ries use motorized treadmills, however, alternative forms of 
exercise such as active pedal-plantar flexion, climbing stairs, 
walking in the hallway or the 6-minute walk test can also be 
employed. Moreover, exercise can help to objectively assess 
the degree of functional limitations posed by PAD, differen-
tiate claudication from pseudoclaudication in patients with 
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response to claudication interventions and guide individual-
ized exercise prescriptions in patients with PAD [1].  
Noninvasive Imaging Techniques 
  Duplex ultrasound provides both vascular imaging and 
flow velocity information and has been shown to be an accu-
rate method to diagnose the location and severity of lower 
extremity PAD with both sensitivity and specificity greater 
than 90% [18]. Accuracy is diminished for the iliac arteries 
in the presence of bowel gas or tortuosity as well as if there 
is dense calcification or multiple stenoses. Quantitative crite-
ria to diagnose stenoses are based on peak systolic velocity 
and peak systolic velocity ratios within or beyond the steno-
sis compared with the adjacent proximal arterial segment, 
the presence or absence of turbulence and preservation of 
pulsatility. A peak systolic velocity ratio greater than 2 indi-
cates stenosis greater than 50% [19-21]. Apart from the ini-
tial diagnosis of the location and degree of stenosis, duplex 
ultrasound is recommended for routine surveillance after 
surgical revascularization with a venous conduit at 1, 3, 6 
and 12 months and then yearly thereafter [1, 7]. On the con-
trary, duplex ultrasound surveillance of synthetic grafts as 
well as after angioplasty procedures is of uncertain value [1]. 
  Recent advances in noninvasive angiography, including 
computed tomographic angiography (CTA) and magnetic 
resonance angiography (MRA), enable excellent noninvasive 
definition of the vascular anatomy to diagnose the location 
and degree of stenosis in PAD. New multi-detector CTA 
technology allows fast imaging of the entire lower extremity 
and abdomen in one breath hold at sub-millimeter voxel 
resolution and it can also provide 3-dimensional reconstruc-
tion images that can be rotated in space to view any oblique 
projection. Both sensitivity and specificity for detection of 
stenosis greater than 50% have been greater than 90% in 
different studies [22-27].  
  The potential advantages of CTA over conventional an-
giography include better evaluation of eccentric stenoses and 
visualization of all collateral vessels as well as surrounding 
tissues. On the other hand, potential disadvantages include 
lower spatial resolution compared to catheter angiography 
and venous opacification or asymmetrical opacification of 
some vessels that can obscure imaging quality of the arteries. 
Compared to MRA, CTA has the potential advantages that 
patients with pacemakers and defibrillators can be imaged 
safely; it has higher resolution; fewer artifacts with metallic 
clips, stents or prostheses; lower cost; and it can provide 
images of calcification in the vessel wall [28, 29]. Con-
versely, disadvantages of CTA include the use of iodinated 
contrast and higher risk of nephrotoxicity as well as expo-
sure to ionizing radiation.  
  In a similar manner, MRA of the extremities can be used 
to diagnose PAD of the lower extremities with high accuracy 
similar to that of intraoperative catheter angiography [30]. A 
meta-analysis comparing MRA with catheter angiography 
demonstrated that sensitivity and specificity of MRA for 
detection of stenoses greater than 50% were both in the 
range of 90-100% [31]. Some studies suggest that MRA is 
superior to catheter angiography in detection of outflow ves-
sels suitable for distal bypass in patients with chronic limb 
ischemia [32, 33]. MRA may be used for preoperative plan-
ning, to define a road map for revascularization procedures 
and has been used anecdotally for follow-up assessment after 
surgical or endovascular revascularization [1]. However, 
MRA has also inherent limitations in that it tends to overes-
timate the degree of stenosis because of turbulence; it cannot 
scan patients with pacemakers or defibrillators; metal stents 
or clips can obscure vascular flow; and use of gadolinium 
was recently associated with rare occasions of renal toxicity 
and nephrogenic systemic fibrosis in patients with elevated 
creatinine [34].  
Contrast Angiography 
  Contrast angiography provides detailed information 
about the arterial anatomy and is recommended as the “gold 
standard” method for evaluation of patients with lower ex-
tremity PAD, especially when revascularization is contem-
plated. Technical improvements with digital subtraction 
techniques that enhance image quality as well as use of sup-
portive modalities, such as intravascular ultrasound, an-
gioscopy, optical coherence tomography and adjunctive 
hemodynamic measurements, such as pressure gradients, 
established catheter angiography as the universally accepted 
method for guiding percutaneous peripheral interventional 
procedures [1, 7]. Angiography carries the inherent risks 
associated with any invasive procedure, including those re-
lated to vascular access (e.g. bleeding, infection, atheroem-
bolism, dissection, vessel disruption or perforation, hema-
toma, pseudoaneurysm, arteriovenous fistula) with rates of 
major complications ranging from 1.9 to 2.9%, which is fur-
ther reduced with operator experience [35]. Anaphylactoid 
reactions occur in fewer than 3% of cases with the risk of 
severe reactions of approximately 0.1% [36]. The risk of 
contrast induced nephropathy is less than 2% in the general 
population, but increases considerably in high-risk patients 
with severe baseline renal dysfunction, diabetes, low cardiac 
output, dehydration, advanced age, multiple myeloma or 
those receiving other nephrotoxic drugs [37, 38]. Optimal 
prevention of contrast induced nephropathy requires vigor-
ous hydration with either 0.9% isotonic normal saline or iso-
tonic sodium bicarbonate solution, use of low-osmolar con-
trast agents, minimizing the overall amount of contrast and 
pretreatment with N-acetylcysteine; various other modalities 
are investigated with unclear effectiveness [37]. 
MANAGEMENT 
  The mainstays of treatment of lower extremity PAD and 
specifically of SFPA disease include risk factor modifica-
tion, an exercise program, pharmacologic treatment and, if 
warranted for symptomatic relief, endovascular or surgical 
revascularization (Figs. 4 and 5). In general, revasculariza-
tion is reserved for patients with significant disability or   
tissue loss, failure of medical therapies, lack of significant 
comorbid conditions, vascular anatomy suitable for planned 
revascularization and a favorable risk/benefit ratio [1, 7].  
Risk Factor Modification and Cardiovascular Risk   
Reduction 
  Since cardiovascular events are the major cause of death 
in patients with PAD [1, 5, 7, 11, 12], modification of tradi-
tional atherosclerotic risk factors is of paramount importance 
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given on smoking cessation and aggressive glycemic control 
in diabetic patients, since both represent the most dominant 
risk factors for PAD.  
  Smoking cessation among patients with symptomatic 
PAD does not improve walking capacity but may reduce the 
severity of claudication and the risk of developing critical 
limb ischemia [39]. Although there are no prospective ran-
domized trials to examine the effects of smoking cessation 
on cardiovascular events in patients with lower extremity 
PAD, given its strong association with both PAD and car-
diovascular disease, it is a class I recommendation in current 
guidelines that comprehensive smoking cessation interven-
tions should be offered to all patients with lower extremity 
PAD, including behavior modification therapies, nicotine 
replacement therapy or bupropion [1, 7]. 
  Within the same concept, aggressive glycemic control in 
diabetics with a target of hemoglobin A1C less than 7% is 
endorsed by both the American College of Cardiol-
ogy/American Heart Association (ACC/AHA) and the 
Trans-Atlantic Inter-Society Consensus (TASC II) for the 
management of PAD as well as the American Diabetes As-
sociation [1, 7, 9]. Although studies of both type 1 and type 
2 diabetes traditionally have shown that aggressive blood 
glucose lowering can prevent microvascular complications, 
this has not been shown for PAD, primarily because these 
studies were neither designed nor powered to examine PAD 
endpoints [40, 41]. However, more recently, an extended 
follow-up of the Diabetes Control and Complications Trial 
[41] demonstrated that intensive glycemic control in type 1 
diabetics can provide long-term beneficial effects on the risk 
of cardiovascular disease [42]. Furthermore, it has been es-
timated that each 1% increase in glycosylated hemoglobin 
level is associated with a 32% and 28% increased risk of 
incident PAD in type 1 and 2 diabetics, respectively [43]. 
  In addition to smoking cessation and aggressive man-
agement of diabetes, treatment of dyslipidemia reduces the 
risk of cardiovascular events in patients with atherosclerosis. 
 
Fig. (4). Overall treatment strategy for peripheral arterial disease. BP – blood pressure; HbA1c – hemoglobin A1c; LDL – low density lipo-
protein; MRA – magnetic resonance angiography; CTA – computed tomographic angiography. Reproduced with permission from Hiatt WR. 
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There is plenty of evidence from large randomized trials and 
meta-analyses [44-47] demonstrating the beneficial effects of 
statin treatment in reducing the incidence of claudication and 
improving pain-free walking time, apart from the well-
recognized reduction in overall cardiovascular morbidity and 
mortality. Moreover, a revision of the National Cholesterol 
Education Program Adult Treatment Panel III guidelines 
classifies individuals with PAD as either “high risk” or “very 
high risk” depending on the presence of coexisting risk fac-
tors and recommends a target LDL cholesterol <100 or <70 
mg/dL for these patients, respectively [48]. These targets are 
also corroborated by the recent ACC/AHA and TASC II 
guidelines for the management of PAD [1, 7]. 
  Similarly, hypertensive patients with PAD should be 
treated accordingly to meet current guidelines targeting 
blood pressure less than 140/90 mmHg; or less than 130/80 
mmHg for patients with diabetes or chronic kidney disease 
[1, 7, 49]. Contrary to the prior belief, b-adrenergic blockers 
do not adversely affect walking capacity nor worsen inter-
mittent claudication in patients with mild and moderate PAD 
and may be particularly beneficial in patients with dimin-
ished left ventricular function [50]. Moreover, angiotensin-
converting enzyme inhibitors and specifically ramipril have 
been shown to reduce the risk of myocardial infarction, 
stroke or vascular death by 25% in patients with PAD [51]. 
Ramipril has also been associated with improvement in 
walking distance in stable claudicants in a single study and 
should be considered in all patients with symptomatic PAD 
who do not have any contraindications to this class of drugs 
[52].  
Exercise and Rehabilitation in Patients with PAD 
  Exercise significantly improves walking time and overall 
walking ability in patients with intermittent claudication and 
should be considered as a primary efficacious treatment in 
PAD [1, 7, 53, 54]. Notably, exercise may be more effective 
than antiplatelet therapy in improving maximal walking time 
and has equivalent efficacy to surgery [54]. Furthermore, 
physical activity both prevents and helps treat many estab-
lished
 atherosclerotic risk factors, including elevated blood 
pressure,
 insulin resistance and glucose intolerance, elevated 
triglyceride
 concentrations and low high-density lipoprotein 
[55]. There is also a well-recognized role of habitual physi-
cal activity in reducing inflammation, which is implicated in 
the pathogenesis of atherosclerosis [56]. The optimal exer-
cise training program for patients with intermittent claudica-
tion involves supervised walking to near-maximal pain 3 
times a week at least for 30 minutes sessions for a period of 
6 months. A meta-analysis of eight randomized trials dem-
onstrated a greater symptomatic benefit with a supervised, as 
opposed to non-supervised, exercise program, involving 
walking on a treadmill three times a week for 12 to 24 
weeks, with the initial workload set to elicit symptoms 
within 3 to 5 minutes of walking [57]. The mechanism by 
which exercise improves symptoms of claudication is un-
clear, but it appears to be unrelated to improvement of the 
ABI or growth of collateral vessels [58].  
Antiplatelet Therapies 
  The Antithrombotic Trialists’ Collaboration meta-
analysis of 135,640 patients at high risk of occlusive arterial 
disease demonstrated that antiplatelet therapy with aspirin 
(75 mg to 325 mg daily) reduces the risk of myocardial in-
farction, stroke and cardiovascular death by 25% in patients 
with PAD [59]. In the same meta-analysis, different doses of 
aspirin were compared suggesting that 75 to 150 mg daily 
doses are at least as effective as higher doses with lower risk 
of gastrointestinal and bleeding complications. Aspirin has 
not been shown to improve claudication, but it delays the 
progression of the disease, reduces the need for intervention 
and reduces graft failure in patients who have undergone 
surgery [59, 60].  
  The Clopidogrel vs. Aspirin in Patients at Risk of 
Ischemic Events (CAPRIE) trial demonstrated that clopi-
dogrel 75 mg daily compared with aspirin 325 mg daily re-
duced the risk of myocardial infarction, stroke or cardiovas-
 
Fig. (5). Algorithm for treatment of the patient with critical limb ischemia. Contraindications are: patients not fit for revascularization; revas-
cularization not technically possible; benefit cannot be expected (i.e. widespread ulceration-gangrene). CLI – critical limb ischemia; MRA – 
magnetic resonance angiography; CTA – computed tomographic angiography. Reproduced with permission from [7]. 302     Current Cardiology Reviews, 2009, Vol. 5, No. 4  Kasapis and Gurm 
cular death by 8.7% with similar bleeding complications in 
high risk patients, with the greatest benefit in the subgroup 
of patients with PAD [61]. On the basis of this single com-
parative trial and considering the higher cost, current guide-
lines recommend clopidogrel as an effective alternative anti-
platelet therapy to aspirin [1, 7]. 
  Dual antiplatelet therapy with a combination of aspirin 
and clopidogrel in high risk patients with PAD was recently 
evaluated and it was not found significantly more
 effective 
than aspirin alone in reducing the rate of myocardial
 infarc-
tion, stroke, or death from cardiovascular causes, whereas 
there was a trend for higher severe bleeding events in the 
dual antiplatelet therapy group [62]. Similarly, ticlopidine, 
an alternative thienopyridine to clopidogrel, is not supported 
by the current guidelines, because of higher risk of signifi-
cant hematologic side effects, including thrombocytopenia, 
thrombotic thrombocytopenic purpura and potentially fatal 
neutropenia [1, 7]. Likewise, there is no benefit of heparin, 
low-molecular weight heparin or oral anticoagulants in pa-
tients with PAD, whereas there is an increased risk of major 
bleeding, especially with oral anticoagulants [63]. Further-
more, the combination of oral anticoagulant and antiplatelet 
therapy in patients with PAD was demonstrated to be not 
more effective than antiplatelet therapy alone in preventing 
major cardiovascular complications, while it was associated 
with an increase in life-threatening bleeding [64]. 
  Use of antiplatelet therapy after an endovascular or sur-
gical revascularization procedure has been shown to improve 
outcomes, although the evidence is not conclusive [65-68]. 
However, based on the overall reduction of the cardiovascu-
lar risk, current guidelines recommend lifelong antiplatelet 
medications (aspirin or clopidogrel) after a revascularization 
procedure to promote patency. Furthermore, standard ther-
apy during endovascular interventions with heparinization is 
recommended to achieve an activated clotting time of 200-
250 msec [7]. The use of alternative antithrombotic agents 
during peripheral vascular interventions, such as low mo-
lecular weight heparin or adjunctive abciximab for complex 
lesions, has been investigated with equivocal results. 
Pharmacologic Treatment for Claudication 
  Cilostazol is a phosphodiesterase type III inhibitor with 
vasodilator and mild antiplatelet properties. A meta-analysis 
of eight randomized controlled trials demonstrated that 
treatment with cilostazol for 12 to 24 weeks significantly 
increased maximal and pain-free walking distance by 50% 
and 67%, respectively, and improved quality of life measures 
in patients with PAD [69]. The recommended dose is 100 
mg twice daily in patients with intermittent claudication and 
is contraindicated in patients with heart failure, because of an 
associated increase in cardiac mortality in this subgroup seen 
with other phosphodiesterase inhibitors, such as milrinone 
[1]. 
  Pentoxifylline, a methylxanthine derivative, has also 
been approved for use in patients with intermittent claudica-
tion, as alternative to cilostazol, at a dose of 400 mg three 
times a day. In a trial comparing cilostazol, pentoxifylline 
and placebo, pentoxifylline was inferior to cilostazol and no 
better than placebo for relief from claudication [70]. How-
ever, two meta-analyses of randomized controlled trials 
demonstrated that pentoxifylline causes a marginal but statis-
tically significant increase in pain-free and maximal walking 
distance [39, 71]. 
  Naftidrofuryl, a 5-hydroxytryptamine type 2 antagonist, 
has been available in European countries for treatment of 
intermittent claudication [7]. In a meta-analysis of 5 studies, 
involving 888 patients, naftidrofuryl at a dose of 600 mg 
daily increased pain-free distance by 26% compared to pla-
cebo [72], whereas in a different meta-analysis there was a 
more marginal but significant increase in maximal and pain-
free walking distances [39]. 
  Other investigated medical treatments, such as garlic, 
testosterone, levocarnitine, propionyl-L-carnitine, L-
arginine, oral vasodilator prostaglandins, vitamin E, ginkgo 
biloba and chelation therapy have been evaluated in clinical 
trials and have not shown to be effective or are marginally or 
less effective than the currently established treatments [1, 7].  
Angiogenic Growth Factors 
  Angiogenic growth factors, such as vascular endothelial 
growth factor (VEGF), recombinant fibroblast growth factor-
2 (rFGF-2) and hypoxia-inducible factor-1, have generated 
considerable enthusiasm as potential treatments of PAD that 
stimulate the development of new vessels. Intra-arterial infu-
sion of rFGF-2 resulted in a significant increase in peak 
walking time in 90 days; however, repeat infusion in 30 days 
was no better [73]. Although there were no adverse events in 
this study, one prior placebo-control study of intravenous 
administration of basic fibroblast growth factor was termi-
nated prematurely because of the development of significant 
proteinuria in 25% of the subjects [74]. Conversely, initial 
studies have not been positive for intramuscular administra-
tion of VEGF [75]. Newer applications involve gene transfer 
strategies of angiogenic proteins with viral or non-viral vec-
tors [76]. Plasmid adjuncts, such as poloxamers, have also 
been used to enhance gene expression [77]. However, more 
studies will be needed to address the overall efficacy and 
safety as well as the mode and frequency of administration 
of angiogenic growth factors in the treatment of PAD.  
Endovascular Treatments and Revascularization 
  Over the past decade there has been a remarkable ad-
vancement in the endovascular treatment of lower extremity 
PAD with the introduction of new interventional techniques 
and devices. According to ACC/AHA guidelines, endovas-
cular treatment of SFPA disease is indicated for individuals 
with significant disability due to intermittent claudication or 
critical limb ischemia when clinical features suggest a rea-
sonable likelihood of symptomatic improvement with endo-
vascular intervention, there has been an inadequate response 
to exercise or pharmacological therapy and when there is a 
favorable risk-benefit ratio [1]. Apart from the clinical and 
angiographic criteria for selection of patients for endovascu-
lar treatment, for stenoses of 50-75% diameter by angiogra-
phy, intravascular translesional pressure gradients have been 
recommended to determine whether these lesions are hemo-
dynamically significant and to predict patient improvement 
after revascularization. Although there is no consensus on 
the diagnostic translesional pressure gradient criteria, the 
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mmHg before or after vasodilators; or a mean gradient of 5 
mmHg and peak systolic gradient of 10, 15 or 20 mmHg; or 
15% peak systolic pressure gradient after administration of a 
vasodilator [78]. The TASC II consensus emphasizes more 
anatomic criteria and recommends endovascular revasculari-
zation for type A lesions and surgery for type D lesions, 
whereas endovascular treatment is preferred for type B le-
sions and surgery for good-risk patients with type C lesions 
(Fig. (6)) [7]. There is a wide variety of established and 
evolving endovascular techniques to treat PAD including 
percutaneous transluminal angioplasty (PTA) with balloon 
dilation, stents, endografts, atherectomy, laser, cutting bal-
loons, drug-coated balloon angioplasty, cryoplasty, percuta-
neous thrombectomy and brachytherapy.  
Percutaneous Transluminal Angioplasty 
  From all the above techniques, PTA is the preferred rec-
ommended initial endovascular treatment for SFPA disease, 
with provisional stenting or use of other adjunctive tech-
niques as salvage therapy for a suboptimal or failed result 
from balloon dilation, i.e. persistent translesional pressure 
gradient, residual diameter stenosis greater than 50%, or 
flow-limiting dissection [1, 7]. 
  The technical and clinical success rate of PTA with pro-
visional stenting for SFPA disease exceeds 93% [79]. Out-
comes after PTA have improved over time, with primary 
patency rates at 1 year ranging from 45% to 84.2% and at 2 
years from 25% to 77.2% [80]. In the STAR registry the 
technical success rate for PTA was 95%, with primary 
 
Fig. (6). TASC classification of femoral popliteal lesions. CFA – common femoral artery; SFA – superficial femoral artery. Reproduced with 
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patency rates of 87% at 1 year, 80% at 2 years, 69% at 3 
years and 55% at 4 and 5 years. Stratified to TASC catego-
ries, the 36-month patency rate was 87% for TASC A le-
sions, 69% for TASC B lesions and 67% for TASC C le-
sions, indicating that TASC C lesions may be treated with 
PTA with results similar to TASC B lesions [81]. Predictors 
of failure of endovascular treatment include critical limb 
ischemia, distal location, occlusion, poor crural runoff ves-
sels, increasing length of lesions, multiple and diffuse le-
sions, diabetes, smoking and renal insufficiency [81-83].  
  Several randomized controlled trials compared the out-
comes of PTA versus surgery in patients with SFPA disease 
and demonstrated similar outcomes [84-86]. More recently, 
the BASIL trial (Bypass versus Angioplasty in Severe 
Ischemia of the Leg), a large multicenter study of 452 pa-
tients with severe limb ischemia randomized to surgery or 
angioplasty, showed similar outcomes in terms of amputa-
tion-free survival with surgery being more expensive than 
angioplasty [87]. Similarly, a cost-effectiveness analysis 
compared PTA and bypass surgery with exercise therapy for 
treatment of claudication and demonstrated that the cost-
effectiveness for PTA was $38,000 per quality-adjusted life 
year compared to $311,000 per quality-adjusted life year for 
bypass surgery [88]. In regards to cost-effectiveness, PTA is 
preferable to surgery as long as the expected 5-year patency 
rate for the treated vessel exceeds 30% [89]. In addition, 
PTA is preferred over surgery, when possible, in patients 
younger than 50 years old, because they have a higher risk of 
graft failure after surgical therapy than do older patients [1]. 
Stents 
  The role of primary stent placement in SFPA disease 
remains controversial. Endovascular stenting avoids the 
problems of early elastic recoil, residual stenosis and flow-
limiting dissection after balloon angioplasty and can thus be 
used for treatment of long and calcified lesions. On the other 
hand, the SFPA is subject to longitudinal stretching, external 
compression, torsion and flexion, which may lead to stent 
fractures and eventually to restenosis. While evolution in 
stent material and design has overcome some of these limita-
tions, the clinical impact remains unclear.  
  Selection of the primary endovascular treatment for pa-
tients with SFPA disease with either PTA or stenting as the 
initial approach was assessed in multiple randomized trials 
producing conflicting results [90-98], with two meta-
analyses demonstrating overall no difference in primary 
patency rates between the two endovascular techniques [79, 
80]. A previous cost-effective analysis of a trial that random-
ized patients with SFPA disease to treatment with a self-
expanding nitinol stent versus PTA demonstrated that the use 
of routine stenting increased the procedure duration, equip-
ment costs and physician services, resulting in initial hospital 
costs $3,500/patient higher for patients randomized to the 
nitinol stent compared to PTA. The authors of that study 
concluded that a strategy of routine stent implantation for 
patients with SFPA disease is not optimal on economic 
grounds and that PTA with provisional stenting should be 
preferred [99]. Based on current evidence and lower equip-
ment cost, recent guidelines recommend PTA as the initial 
preferred option for endovascular treatment of symptomatic 
SFPA lesions with bail-out stent placement after a subopti-
mal or failed result from balloon dilation [1, 7].  
  Stent designs have changed over the years, however, and 
a recent randomized trial involving 104 patients with severe 
claudication or critical limb ischemia showed significantly 
higher patency rates at 1 and 2 years for long SFPA lesions 
treated with primary nitinol stent implantation compared to 
PTA with provisional stenting (63% and 37% at 1 year; 
54.3% and 30.8% at 2 years, respectively) [97, 98]. This 
finding supports the concept that the improvement in nitinol 
stent design, including improvement in radial strength, the 
ability to recover from being crushed and reduced foreshort-
ening, has led to better anatomical and clinical outcomes 
than the older stainless-steel stents. This is in agreement with 
previous studies showing superior patency outcomes with 
the new generation nitinol stents compared to stainless-steel 
stents [100, 101]. Conversely, a recent randomized trial in-
volving 244 patients with short SFPA disease using a differ-
ent self-expandable nitinol stent demonstrated similar 
restenosis rates at 1 year with primary stenting and PTA with 
provisional stenting (31.7% and 38.6%, respectively).  
  The frequency of nitinol stent fractures in these two re-
cent trials was only 2% and 12% at 12 months, respectively 
[96, 98] and in the study with the highest frequency of stent 
fractures the binary restenosis rate was similar in fractured 
and non-fractured stents [98]. However, the occurrence of 
stent fractures in SFPA and their association with in-stent 
restenosis remains an important consideration. A trial inves-
tigating the occurrence and the clinical impact of stent frac-
tures after femoropopliteal stenting with nitinol stents sug-
gested a considerable risk of stent fractures (24.5%), espe-
cially following long segment femoral artery stenting. Stent 
fractures in this study were associated with a higher in-stent 
restenosis and re-occlusion rate after a mean follow-up of 11 
months [102].  
  Based on the discrepancy of these results and the im-
provement of stent designs over the years, more data is re-
quired to elucidate whether other factors, such as the length 
of the stented segment as well as the stent design and stent 
surface, are more likely to affect stent patency than stent 
fractures. Currently, there are three ongoing randomized 
trials in the recruitment phase comparing nitinol stents 
(SMART Cordis, Miami, FL) with balloon angioplasty for 
SFPA disease as well as one trial comparing two different 
types of nitinol stents (Table 1).  
Drug-Eluting Stents and Balloons 
  Initial attempts at transferring the benefits seen with drug 
eluting stents in the coronaries to the femoropopliteal arteries 
have not yet been successful. The SIROCCO II study, a ran-
domized trial of sirolimus-coated nitinol stents compared to 
bare metal nitinol stents for SFPA disease, demonstrated no 
significant difference in patency rates. At 24 months of fol-
low-up, the restenosis rate in the sirolimus group was 22.9% 
versus 21.1% in the bare metal stent group [103]. Currently, 
there is an ongoing large randomized trial (ZILVER PTX) in 
the recruitment phase using a paclitaxel-coated nitinol stent 
versus angioplasty in the treatment of symptomatic SFPA 
disease (Table 1).  
  Recently, promising results were published from a ran-
domized multicenter trial, assigning 154 patients with steno-
sis or occlusion of femoropopliteal artery to treatment with 
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balloons with paclitaxel dissolved in the contrast medium, or 
uncoated balloons without paclitaxel [104]. Use of pacli-
taxel-coated angioplasty balloons during PTA for SFPA dis-
ease was associated with significant reductions in late lumen 
loss and target-lesion revascularization (target-lesion revas-
cularization at 6 months, 37% in the control group vs. 4% in 
the group treated with paclitaxel-coated balloons; at 24 
months, the rates increased to 52% and 15%, respectively). 
No significant benefit was seen with the use of a paclitaxel-
containing contrast medium. A similar smaller randomized 
trial comparing paclitaxel-coated with plain balloon an-
gioplasty in SFPA disease (PACCOCATH-FEM I) has com-
pleted enrollment (Table 1).  
Endografts 
  Early results from the use of Dacron-covered stent grafts 
were disappointing due to little patency benefit and high 
early and late restenosis rates, with a considerable rate of 
inflammatory complications, such as fever and pain [105]. 
However, the development of new self-expandable stent en-
dografts, with an expanded polytetrafluoroethylene tube in-
side a nitinol support structure, yielded more promising re-
sults. A prospective single-arm safety and efficacy study of 
the Hemobahn endoprosthesis (W. L. Gore & Associates, 
Flagstaff, AZ) in 80 limbs with occlusive femoral-popliteal 
lesions demonstrated a primary patency of 90% at 6 months 
and 79% at 12 months [106]. A single-center small random-
ized trial of 28 patients compared PTA with the Hemobahn 
endograft, , and demonstrated a statistically significant im-
provement in both patency and clinical outcome with the 
endograft [107]. Subsequent to this report, the graft delivery 
system was modified and it was renamed Viabahn endopros-
thesis. A prospective single-arm study of 87 limbs in 76 pa-
tients with long atherosclerotic occlusive disease of the 
SFPA (mean lesion length 14.2 cm, with 92% of lesions with 
at least 7 cm in length) treated with the Viabahn endograft 
demonstrated primary patency rates 76% at 1 year and 55% 
at 4 years [108]. Furthermore, a recent randomized prospec-
tive study of 100 patients comparing percutaneous treatment 
of SFPA disease with the Viabahn stent graft and surgical 
Table 1.  Ongoing Randomized Controlled Trials of Balloon Angioplasty and/or Stents in Symptomatic SFA Disease. There are 
also five Ongoing Non-Randomized Trials Evaluating Safety and Efficacy of Different Types of Stents (NCT 
ID#00180505, N=120; NCT ID#00475566, N=100; NCT ID#00530712, N=287; NCT ID#00496041, N=200; NCT 
ID#00542646, N=45). Data from http://www.ClinicalTrials.gov 
 
Study 
Name 
Super UK  Sit-UP  DURAVEST  ZILVER 
PTX 
GORE 
VIABAHN 
SIROCCO 
SFA 
Super SL  PACCOCATH-
FEM I 
Status  Recruiting Recruiting Recruiting Recruiting  Recruiting 
Active, 
Not recruiting 
Active, 
Not recruiting 
Active, 
Not recruiting 
Phase  IV  IV  IV  I IV II  IV I-II 
NCT  ID 00232843 00309595 00289055 00120406  00228384  00232869 00235131  00472472 
Treatment 
arm I 
Cordis 
SMART 
nitinol stent 
Cordis 
SMART 
nitinol stent 
Cordis 
SMART 
nitinol stent 
ZILVER 
PTX Drug 
eluting stent 
VIABAHN 
endoprosthesis 
Sirolimus 
coated Cordis 
SMART 
nitinol stent 
Cordis 
SMART 
nitinol stent 
Paclitaxel-coated 
balloon an-
gioplasty 
Treatment 
arm II 
Balloon 
Angioplasty 
Balloon 
Angioplasty 
Balloon An-
gioplasty 
Balloon 
Angioplasty 
Bare nitinol 
stent 
SMART bare 
metal stent 
Bard Lumin-
exx stent 
Plain Balloon 
Angioplasty 
Type of 
study 
Randomized 
1:1, con-
trolled, pro-
spective, 
multicenter 
Randomized 
1:1, con-
trolled, pro-
spective, 
multicenter 
Randomized 
1:1, con-
trolled, pro-
spective, 
multicenter 
Randomized 
1:1, con-
trolled, pro-
spective, 
multicenter 
Randomized 
1:1, controlled, 
prospective, 
multicenter 
Randomized 
1:1, con-
trolled, dou-
ble-blinded, 
prospective, 
multicenter 
Randomized 
1:1, con-
trolled, pro-
spective, 
multicenter 
Randomized 1:1, 
controlled, dou-
ble-blinded, 
prospective, 
multicenter 
Size  (N)  150 120 120 480  150  90  200  79 
Inclusion 
Symptomatic 
SFA disease 
(5-14.5 cm) 
Symptomatic 
SFA disease 
(5-22 cm) 
Symptomatic 
SFA disease 
(5-14.5 cm) 
Symptomatic 
SFA disease 
(<7 cm in 
phase I and 
<14 cm in 
phase II) 
Symptomatic 
SFA disease 
(>8cm) 
Symptomatic 
SFA disease 
Symptomatic 
SFA disease 
(5-22 cm) 
Symptomatic 
SFA disease 
Primary 
endpoint 
Primary 
patency by 
duplex ultra-
sound at 1 
year 
Primary 
patency by 
duplex ultra-
sound at 1 
year 
Primary 
patency by 
duplex ultra-
sound at 1 
year 
Primary 
patency by 
duplex ultra-
sound at 1 
year 
Primary 
patency at 3 
years 
In-stent 
stenosis via 
quantitative 
angiography 
at 6 months 
Primary 
patency by 
duplex ultra-
sound at 1 
year 
Angiographic 
lumen loss at 6 
months 
Start date  3/2005  12/2005  11/2005  3/2005  9/2005  2/2001  5/2005  4/2004 
Completion 
date 
8/2008 4/2008 12/2008  N/A  12/2010 12/2008 3/2008  6/2007 
NCT ID= ClinicalTrials.gov Identifier; SFA=superficial femoral artery; N/A= not available. 
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bypass with synthetic graft showed similar primary patency 
rates at 12 months in both groups (73.5% and 74.2%, respec-
tively) [109]. The Viabahn endoprosthesis is currently ap-
proved by the US Food and Drug Administration (FDA) for 
use in patients with symptomatic superficial femoral arterial 
lesions with reference vessel diameters of 4.8 to 7.5 mm and 
unpublished data from the FDA approval letter randomizing 
197 limbs with SFPA disease to Viabahn stent graft vs. PTA 
demonstrated similar technical success, primary patency and 
target vessel revascularization (TVR) rates at 12 months 
[110]. Notably, when “technical success” and “primary 
patency” were re-defined to be consistent with the literature, 
these endpoints appeared favoring the Viabahn endograft. At 
present, there is an ongoing randomized, prospective, multi-
center trial examining the performance of the Viabahn endo-
prosthesis compared to bare metal nitinol stents in long 
SFPA lesions (>8cm) with a planned 3-year follow-up (Ta-
ble 1). The results of this trial may provide more solid evi-
dence supporting the use of this technology. 
Adjunctive Endovascular Therapies 
  There are many emerging adjunctive endovascular tech-
nologies, such as atherectomy, laser angioplasty, cutting bal-
loon angioplasty, cryoplasty and brachytherapy, that have 
been investigated and their role remains controversial.  
  Directional atherectomy was developed with the idea to 
increase procedural luminal gain while avoiding barotraumas 
and vessel recoil. Initial results using the Simpson Athero-
Cath (Guidant, Temecula, CA) were disappointing suggest-
ing that directional atherectomy might actually be worse than 
plain angioplasty [111]. However, in the recent years there 
has been a new interest in debulking devices with the devel-
opment of a new atherectomy system, the SilverHawk Ath-
erectomy Catheter (Fox Hollow Technologies, Redwood 
City, CA) as well as excimer laser atherectomy catheters. 
There are no prospective randomized trials comparing exci-
sional atherectomy with the SilverHawk catheter to PTA or 
stenting. The initial long-term outcomes from a single-center 
non-randomized study demonstrated primary patency at 18 
months of 73% for de novo lesions and much lower for na-
tive vessel restenosis (42%) or in-stent restenosis (49%) 
[112]. The potential role of excisional atherectomy with the 
SiverHawk catheter for the treatment of critical limb ische-
mia is to be further evaluated in an ongoing randomized trial 
comparing the SilverHawk atherectomy with surgical bypass 
(PROOF trial: Plaque Removal versus Open Bypass Surgery 
for Critical Limb Ischemia). New devices that permit simul-
taneous rotational atherectomy and aspiration of plaque ma-
terial or thrombus have been recently designed and evaluated 
in pilot studies [113]. 
  Excimer laser atherectomy uses flexible fiberoptic cathe-
ters to deliver intense bursts of ultraviolet energy in short 
pulse durations with the potential advantage to treat long 
occlusions and complex disease. This technology has been 
evaluated for long SFPA occlusions (mean length of 19.4 
cm) with high immediate technical success (90.5%), but dis-
appointing 1-year primary patency rates (65.1%). However, 
intensive surveillance using objective testing followed by 
prompt repeat intervention demonstrated 1-year secondary 
patency rates of 75.9% [114]. Results have been more prom-
ising for the treatment of critical limb ischemia with laser 
angioplasty in the Laser Angioplasty for Critical Limb 
Ischemia (LACI) trial, a multicenter prospective registry of 
155 limbs with complex, long (>16 cm) and diffuse disease, 
demonstrating an excellent limb salvage rate of 93% at 6 
months [115]. A major limitation of the laser atherectomy 
catheters has been the inability to create a channel much 
larger than the catheter diameter. To overcome this limita-
tion, a new design of laser catheter has been developed, the 
TURBO-Booster catheter (Spectranetics, Colorado Springs, 
CO), which allows the laser to directionally ablate tissue to 
obtain a larger diameter. The safety and efficacy of this de-
vice is currently being evaluated in the multicenter CELLO 
trial (ClirPath Excimer Laser to Enlarge Lumen Openings).  
  Remote endarterectomy is a hybrid of minimally invasive 
surgery and endovascular techniques for treatment of long 
segment SFPA lesions with a single small groin incision. 
Despite the initial disappointing results [116], a recent study 
combining this technique with placement of an aSpire stent, 
an expanded polytetrafluoroethylene (ePTFE) covered niti-
nol stent with high radial strength, in long SFPA lesions 
(mean length 28.2 cm) demonstrated a primary cumulative 
patency rate of 60.6% at 33 months, with 25% of patients 
requiring secondary PTA and/or stent during follow-up 
[117]. At present there is an ongoing randomized control 
trial evaluating remote endarterectomy with placement of an 
aSpire stent versus bypass surgery in patients with long (>10 
cm) symptomatic superficial femoral artery disease (REVAS 
- Remote Endarterectomy Versus Suprageniculate Femoro-
popliteal Bypass) with a planned 5-year follow-up. 
  Cutting balloon angioplasty is another evolved endovas-
cular technology with the idea to reduce stretching and over-
expansion of the vessel wall by inducing longitudinal cuts 
into the plaque and the inner layers of the vessel wall, with 
the potential of use in calcified, rigid and undilatable lesions. 
A small randomized study to evaluate cutting balloon an-
gioplasty in comparison to plain balloon angioplasty for 
SFPA disease was terminated prematurely after the device 
has been recalled by the manufacturer due to potential shaft 
separation of the catheter [118]. 
  Another plaque modulation technology that has been 
evaluated with equivocal results is cryoplasty, using an 
automated liquid nitrogen deployment system to temporarily 
freeze the intima and media wall layers during balloon dila-
tion with the thought to induce a more benign healing proc-
ess and reduce neointima formation and subsequent resteno-
sis following angioplasty. In a multicenter prospective cohort 
of 102 patients with symptomatic SFPA disease (mean lesion 
length 4.7 cm), this technique had an immediate technical 
success rate of 85.3%, primary patency rate by duplex ultra-
sound of 70.1% at 9 months and clinical patency rate (de-
fined as freedom from target lesion revascularization) of 
75% at 3 years [119, 120]. These results appear very similar 
to plain angioplasty and, in the absence of comparative re-
sults as well as higher device cost, this technology is not 
justified for general application. 
  Similarly, trials of brachytherapy, using a catheter to de-
liver radiation to the lesion in adjunction with PTA to pre-
vent restenosis, have yielded inconsistent results. In a ran-
domized trial adjunctive endovascular brachytherapy 
(EVBT) at a dose of 12 to 14 Gy combined with PTA in 
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seemingly beneficial short-term effects of EVBT with PTA 
were not sustained at 5-year follow-up, with no robust dif-
ferences compared to PTA alone [121]. Likewise, the 5-year 
results from the prospective randomized Vienna-2 trial, 
which was designed to evaluate the safety and effectiveness 
of adjunctive EVBT compared with no further treatment 
after successful revascularization in patients with long-
segment femoropopliteal lesions demonstrated a late “catch-
up” phenomenon [122]. Although at 6 months there was a 
significant reduction in restenosis for the PTA plus EVBT 
group versus the PTA alone group (29.4% vs. 56.9%, respec-
tively) [123], after 5 years the recurrence rate was similar in 
both groups (72.5%) [122]. A similar dose regimen from the 
same investigators was used to prospectively evaluate the 
effectiveness of EVBT in the prevention of restenosis after 
femoropopliteal stent implantation in high-risk patients and 
failed to improve 6-month patency because of a high inci-
dence of early and late thrombotic occlusion [124]. An ear-
lier randomized trial demonstrated that late acute thrombotic 
occlusion in patients receiving EVBT after stenting occurred 
in 27% of patients undergoing EVBT with stenting, espe-
cially after discontinuation of clopidogrel treatment, versus 
no events occurred in the patients with stents and without 
EVBT or those undergoing EVBT after simple balloon an-
gioplasty [125]. A novel approach to deliver external-beam 
radiation (EBR) to de novo SFPA lesions after PTA has been 
developed and evaluated in a randomized controlled trial. At 
1 year follow-up, a single session of external beam radiation 
with 14 Gy of the femoropopliteal angioplasty site signifi-
cantly reduced angiographic restenosis compared to the con-
trol and the lower-dose groups [126]. At the short-term, EBR 
was also shown to decrease restenosis rates in patients with 
SFPA disease treated with stents, with a lower incidence of 
thrombotic events than EVBT [127]. However, the late 
“catch –up” phenomenon observed with EVBT necessitates 
a longer follow-up to determine the potential benefit of ex-
ternal-beam radiation.  
Surgical Revascularization 
  Surgical treatment of lower extremity ischemia is indi-
cated for patients with claudication and significant functional 
disability or critical limb ischemia, after failure of conserva-
tive or endovascular therapy, who have a reasonable likeli-
hood of symptomatic improvement, favorable limb arterial 
anatomy and low cardiovascular risk for surgical revascu-
larization [1]. With the evolution of endovascular technology 
and interventional techniques as well as their equivalent effi-
cacy, lower cost and lower peri-procedural risk, surgery has 
become a second-line revascularization option and is cur-
rently recommended only for TASC D lesions [7]. Further-
more, surgery should be avoided, if possible, in patients 
younger than 50 years old, since they have a more virulent 
form of atherosclerosis and subsequently a higher frequency 
of graft failure requiring revisions and replacement [1].  
  Once the decision to proceed with surgical intervention is 
undertaken, the type of revascularization should be elected 
based on different variables, such as location and severity of 
disease, anatomy, general medical condition, prior revascu-
larization attempts and the desired outcome. As a general 
rule, in patients with combined inflow and outflow disease, 
inflow problems are corrected first, since improvement of 
the inflow may diminish the symptoms of claudication and 
reduce the likelihood of distal graft thrombosis from low 
flow [1]. In the case of SFPA disease, two major factors that 
can modify the result of the procedure are the type of the 
conduit and the site of the distal anastomosis. The superior 
rates of immediate and long-term patency rates favor auto-
genous vein grafts as opposed to prosthetic conduits for both 
above- or below-the-knee bypasses [128-130]. The 5-year 
patency rates of femoropopliteal bypass grafts are reported 
as 80% for vein grafts, 75% for above-the-knee synthetic 
grafts and 65% for below-the-knee synthetic grafts [131]. 
Patients undergoing surgical bypass for lower extremity 
ischemia should be entered into a clinical surveillance pro-
gram that consists of interval history and vascular exam as 
well as measurement of resting and, if possible, post-exercise 
ABIs and duplex imaging of the entire length of the graft 
with measurements of peak systolic velocities and calcula-
tion of the velocity ratios across all lesions in the immediate 
postoperative period and at regular intervals (usually every 6 
months) for at least 2 years [1, 7]. Major amputation in pa-
tients with critical or acute limb ischemia should be reserved 
only when the limb is unsalvageable, i.e., when there is 
overwhelming infection that threatens the patient’s life, ex-
tensive necrosis or refractory ischemic rest pain [1, 7]. 
CONCLUSION 
  As the population ages, it is anticipated that the preva-
lence of peripheral vascular disease will increase. Within the 
past decade there has been an unprecedented evolution of the 
endovascular technologies and vital improvements are ex-
pected in the next decade. Percutaneous procedures will con-
tinue to replace open surgery. The chief challenge in the 
management of peripheral arterial disease would be retooling 
of the health system to focus on identifying patients with 
PAD and taking the enormous opportunity and responsibility 
to refine and aggressively manage the atherosclerotic risk 
factors in these patients. An additional challenge will be to 
reorganize clinical and basic research to ensure that investi-
gators are trained to design relevant studies and undertake 
the difficult but necessary task of collecting more definitive 
data to support therapeutic measures, ensure appropriateness 
of care and promote development of newer strategies to pre-
vent and treat PAD. 
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